Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX) hit a new 52-week low on Monday . The stock traded as low as $15.83 and last traded at $15.95, with a volume of 61229 shares changing hands. The stock had previously closed at $16.69.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright assumed coverage on Bicara Therapeutics in a report on Friday, December 6th. They issued a “buy” rating and a $42.00 price objective for the company. Cantor Fitzgerald began coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating on the stock. TD Cowen began coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Morgan Stanley initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $43.00.

Bicara Therapeutics Stock Down 5.2 %

The stock has a fifty day moving average price of $20.10.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. First Turn Management LLC acquired a new position in Bicara Therapeutics during the 3rd quarter worth approximately $14,324,000. Vestal Point Capital LP bought a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $10,825,000. FMR LLC bought a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $57,913,000. Braidwell LP bought a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $42,219,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $9,474,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.